AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31532902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir (DRV/r) plus raltegravir (RAL)
Number of subjects: 201
Study 31532902 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir (DRV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Number of subjects: 201
Study 29730918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Ginseng Rg3
Number of subjects: 414
Study 29730918 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy combined with placebo
Number of subjects: 414
Study 27114413 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dexamethasone (0.15 mg/kg before ESD)
Number of subjects: 40
Study 27114413 — intervention group
Group type: COMPARATOR
Intervention: Postoperative dexamethasone (placebo before ESD, dexamethasone after ESD)
Number of subjects: 40
Study 27114413 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dexamethasone
Number of subjects: 40
Study 27114413 — intervention group
Group type: COMPARATOR
Intervention: Postoperative dexamethasone
Number of subjects: 40
Study 25203167 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (low-frequency rTMS over the right orbitofrontal cortex)
Number of subjects: 0
Study 25203167 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 23015655 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin, 2 mg once daily for 12 months
Number of subjects: 60
Study 23015655 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 20806768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet (Group T)
Number of subjects: 30
Study 20806768 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 30
Study 17331931 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 450
Study 17331931 — intervention group
Group type: COMPARATOR
Intervention: Transdermal diclofenac patch
Number of subjects: 450
Study 17331931 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (Control)
Number of subjects: 450
Study 16361616 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2/3 h, carboplatin (AUC = 6), tirapazamine 260 mg/m2 (escalated to 330 mg/m2 in cycle 2 if tolerable)
Number of subjects: 367
Study 16361616 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (no tirapazamine)
Number of subjects: 367
Study 12013693 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction
Number of subjects: 81
Study 12013693 — intervention group
Group type: COMPARATOR
Intervention: 2D presentations
Number of subjects: 81
Study 11532465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel (LNG/EE)
Number of subjects: 350
Study 11532465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 9468459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide plus triamterene)
Number of subjects: 27
Study 9468459 — intervention group
Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitor (trandolapril)
Number of subjects: 27
Study 9468459 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (amlodipine, added after 3 months if required)
Number of subjects: 27
Study 9468459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during run-in period)
Number of subjects: 27
Study 8181121 — intervention group
Group type: EXPERIMENTAL
Intervention: h-SOD (10 mg/kg intravenous bolus followed by 0.2 mg.kg-1.min-1 infusion)
Number of subjects: 120
Study 8181121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3310630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (n = 31)
Number of subjects: 68
Study 3310630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 68
Study 31670998 — intervention group
Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone caproate (250 mg/IM weekly until 37 weeks' gestation)
Number of subjects: 114
Study 29630639 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 29
Study 29630639 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 29
Study 27163358 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise with pancreatic clamp
Number of subjects: 2
Study 27163358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise without pancreatic clamp
Number of subjects: 2
Study 27163358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise in patients with T2D
Number of subjects: 2
Study 25669920 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Lactobacillus rhamnosus) low-dose (4 × 10(9) CFU/day)
Number of subjects: 123
Study 25669920 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Lactobacillus rhamnosus) high-dose (8 × 10(9) CFU/day)
Number of subjects: 123
Study 25669920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 23889923 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone as an add-on therapy to verapamil
Number of subjects: 0
Study 23889923 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with verapamil
Number of subjects: 0
Study 20946690 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone hotline intervention for postpartum support accessed for the first four months after delivery
Number of subjects: 353
Study 20946690 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone hotline intervention with algorithms developed by the study team
Number of subjects: 353
Study 20946690 — intervention group
Group type: EXPERIMENTAL
Intervention: Questions related to mothers
Number of subjects: 353
Study 20946690 — intervention group
Group type: EXPERIMENTAL
Intervention: Questions related to infants
Number of subjects: 353
Study 18958776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print communications delivered by mail (N = 288)
Number of subjects: 599
Study 18958776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontailored print communications delivered by mail (N = 288)
Number of subjects: 599
Study 18958776 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer intervention materials (N = 288)
Number of subjects: 599
Study 18958776 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 311)
Number of subjects: 599
Study 18958776 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater program exposure/engagement
Number of subjects: 599
Study 16231168 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (150 mg b.d. for 7 days)
Number of subjects: 24
Study 16231168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12791812 — intervention group
Group type: COMPARATOR
Intervention: (123)I‐beta‐CIT SPECT
Number of subjects: 45
Study 12791812 — intervention group
Group type: COMPARATOR
Intervention: Striatal V(3)
Number of subjects: 45
Study 12791812 — intervention group
Group type: COMPARATOR
Intervention: Midbrain outcome measures in PD patients with depression
Number of subjects: 45
Study 10654060 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation program
Number of subjects: 26
Study 10654060 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard program augmented with a perturbation training program
Number of subjects: 26
Study 8711640 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg twice daily for 10 days
Number of subjects: 0
Study 8711640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1506213 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar preparation applied twice weekly for 8 weeks (mode I)
Number of subjects: 15
Study 1506213 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar preparation applied daily for 8 weeks (mode II)
Number of subjects: 15
Study 1506213 — intervention group
Group type: EXPERIMENTAL
Intervention: Coal tar preparation used under occlusion for 30 min every second day for 4 weeks (mode III)
Number of subjects: 15
Study 31006669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean platelet volume (MPV) levels above 11 fL
Number of subjects: 658
Study 31006669 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-pro-BNP levels above 125 pg/ml, thrombocytopenia, atrial fibrillation/flutter
Number of subjects: 658
Study 31006669 — intervention group
Group type: COMPARATOR
Intervention: MPV values
Number of subjects: 658
Study 29471988 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon (PCB) Angioplasty
Number of subjects: 64
Study 29471988 — intervention group
Group type: COMPARATOR
Intervention: Conventional Balloon Angioplasty (PTA)
Number of subjects: 64
Study 26431684 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 94
Study 26431684 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related EFT
Number of subjects: 94
Study 26431684 — intervention group
Group type: COMPARATOR
Intervention: Control (recalling episodic past events)
Number of subjects: 94
Study 25234015 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate 1% eye drops 4 times per day for 5 days after SLT
Number of subjects: 0
Study 25234015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% eye drops 4 times per day for 5 days after SLT
Number of subjects: 0
Study 25234015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 0
Study 21740467 — intervention group
Group type: COMPARATOR
Intervention: Diet with 12% fat
Number of subjects: 64
Study 21740467 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 26% fat
Number of subjects: 64
Study 21740467 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 40% fat
Number of subjects: 64
Study 21740467 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 54% fat
Number of subjects: 64
Study 20202002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day) for a maximum of 4 weeks
Number of subjects: 71
Study 20202002 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 71
Study 20202002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 71
Study 17703640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily
Number of subjects: 12092
Study 17703640 — intervention group
Group type: COMPARATOR
Intervention: Usual care / Unfractionated heparin
Number of subjects: 12092
Study 16385658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg before the induction of anesthesia
Number of subjects: 50
Study 16385658 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study 11959735 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 200
Study 11959735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 200
Study 9708713 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedy (Vertigoheel)
Number of subjects: 119
Study 9708713 — intervention group
Group type: COMPARATOR
Intervention: Betahistine hydrochloride (active control)
Number of subjects: 119
Study 7609169 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 50
Study 7609169 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate
Number of subjects: 50
Study 7609169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm therapy
Number of subjects: 50
Study 7609169 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 50
Study 2227172 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program provided by a nurse including one to three teaching sessions, reading material, audiotapes, and telephone follow‐up.
Number of subjects: 94
Study 2227172 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program (experimental group)
Number of subjects: 94
Study 2227172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 91483 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 180-210 mg/day
Number of subjects: 27
Study 91483 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 70-90 mg/day
Number of subjects: 27
Study 91483 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 31120313 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine ointment
Number of subjects: 25
Study 31120313 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 25
Study 28148473 — intervention group
Group type: EXPERIMENTAL
Intervention: PedAMINES
Number of subjects: 20
Study 28148473 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation methods
Number of subjects: 20
Study 26455190 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (10 mg/kg) injected intravenously approximately 10 minutes before tourniquet release
Number of subjects: 60
Study 26455190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 60
Study 26455190 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA group
Number of subjects: 60
Study 26455190 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 23355148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 1 μg kg(‐1) over 10 min, followed by constant intravenous infusion 0.7 μg kg(‐1) h(‐1))
Number of subjects: 50
Study 23355148 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study 23355148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50
Study 21393261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and colour Doppler-guided sclerosing polidocanol injections
Number of subjects: 52
Study 21393261 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound and colour Doppler-guided arthroscopic shaving
Number of subjects: 52
Study 19726302 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 53
Study 19726302 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 53
Study 17853766 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling method for regulating wei and strengthening brain
Number of subjects: 200
Study 17853766 — intervention group
Group type: COMPARATOR
Intervention: Normal needling method (control group)
Number of subjects: 200
Study 15082493 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 64
Study 15082493 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 64
Study 15082493 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatic diagnosis
Number of subjects: 64
Study 11319482 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (trivalent subvirion vaccine, 15mg of surface antigens)
Number of subjects: 344
Study 11319482 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 344
Study 11319482 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 344
Study 9141738 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone prompt by a medical researcher (Group A)
Number of subjects: 373
Study 9141738 — intervention group
Group type: COMPARATOR
Intervention: Telephone prompt by a nonmedical research assistant (Group B)
Number of subjects: 373
Study 7951402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol, 50 micrograms/day (Estraderm TTS 50) for 14 days, followed by transdermal combination of 17 beta‐estradiol (50 micrograms/day) and norethisterone acetate (NETA) 250 micrograms/day for the next 14 days (Group A)
Number of subjects: 21
Study 7951402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol, 50 micrograms/day (Estraderm TTS 50) for 28 days, adding oral medroxyprogesterone acetate (MPA), 10 mg/day, during the final 14 days (Group B)
Number of subjects: 21
Study 3299565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 120 mg daily
Number of subjects: 92
Study 3299565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 60 mg daily
Number of subjects: 92
Study 3299565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31012984 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 single doses (20, 60, 150, 300, 600, 1000, 1500 mg)
Number of subjects: 53
Study 31012984 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 multiple doses (150 mg twice daily for 14 days; 600 and 1000 mg once daily)
Number of subjects: 53
Study 31012984 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg (tablet vs capsule)
Number of subjects: 53
Study 31012984 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1690 (various doses)
Number of subjects: 53
Study 31012984 — intervention group
Group type: COMPARATOR
Intervention: GLPG1690 (tablet formulation)
Number of subjects: 53
Study 27901329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46
Study 27901329 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 46
Study 25474337 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop Sets (DS)
Number of subjects: 14
Study 25474337 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel (FW)
Number of subjects: 14
Study 25474337 — intervention group
Group type: COMPARATOR
Intervention: Plyometrics (PL)
Number of subjects: 14
Study 25474337 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Voluntary Isometric Contraction (MVIC)
Number of subjects: 14
Study 25474337 — intervention group
Group type: EXPERIMENTAL
Intervention: TMG measurements of maximal radial displacement of the muscle belly (Dm)
Number of subjects: 14
Study 25474337 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraction time between 10 and 90% of Dm (Tc)
Number of subjects: 14
Study 25474337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean muscle contraction velocities from the beginning until 10% (V10) and 90% of Dm (V90)
Number of subjects: 14
Study 22759088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin treatment for 40 days
Number of subjects: 99
Study 20655703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue trills (EG)
Number of subjects: 37
Study 20655703 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercises (CG)
Number of subjects: 37
Study 19751459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) 5+40 mg/d
Number of subjects: 1684
Study 19751459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) 10+40 mg/d
Number of subjects: 1684
Study 19751459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ) 10+40+12.5 mg/d
Number of subjects: 1684
Study 19751459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ) 10+40+25 mg/d
Number of subjects: 1684
Study 17456720 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 339
Study 15172210 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 min light exposure to 10,000 lux for 60 days
Number of subjects: 0
Study 15172210 — intervention group
Group type: COMPARATOR
Intervention: 20 min light exposure to 10,000 lux for 60 days
Number of subjects: 0
Study 11223704 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclamptic women in labor
Number of subjects: 38
Study 11223704 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant controls in labor
Number of subjects: 38
Study 9741068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40
Study 9741068 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 40
Study 9741068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8277066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anistreplase (30 U) given at home
Number of subjects: 311
Study 8277066 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anistreplase (30 U) given in the hospital
Number of subjects: 311
Study 2929440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacemakers (various types)
Number of subjects: 46
Study 2929440 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-sensing pacemakers (Activitrax and Sensolog)
Number of subjects: 46
Study 2929440 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory-sensing pacemakers (Biorate and Meta)
Number of subjects: 46
Study 2929440 — intervention group
Group type: EXPERIMENTAL
Intervention: All pacemakers studied
Number of subjects: 46
Study 2929440 — intervention group
Group type: COMPARATOR
Intervention: Constant-rate ventricular pacing (VVI)
Number of subjects: 46
Study 27992296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercise with elastic bands
Number of subjects: 0
Study 27992296 — intervention group
Group type: COMPARATOR
Intervention: Traditional trunk-muscle-stabilizing exercise
Number of subjects: 0
Study 26370515 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Coated Balloon (DCB) angioplasty
Number of subjects: 120
Study 26370515 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 120
Study 26370515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DCB and DES
Number of subjects: 120
Study 26231519 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Intensity 1 (MI1) - Specialized antenatal breastfeeding education session for fathers with supporting print materials
Number of subjects: 1600
Study 26231519 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Intensity 2 (MI2) - Antenatal and postnatal social support intervention delivered via a smartphone application
Number of subjects: 1600
Study 26231519 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) - Combination of MI1 and MI2 interventions
Number of subjects: 1600
Study 26231519 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Control Group (CG)
Number of subjects: 1600
Study 23948351 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg, three times per day)
Number of subjects: 400